HIGH-DOSE CYCLOPHOSPHAMIDE AND HIGH-DOSE VP-16-213 FOR RECURRENT OR REFRACTORY SMALL-CELL LUNG-CANCER - A PHASE-II STUDYPostmus, P. E., MULDER, N. H., De Vries- Hospers, H. G., Mulder, P. O. M., Maas, A., Meinesz, A. F., Sleijfer, D. T. & De Vries, E. G. E., Dec-1985, In : European journal of cancer & clinical oncology. 21, 12, p. 1467-1470 4 p.
Research output: Contribution to journal › Article › Academic › peer-review
n nine patients with recurrent or refractory small cell lung cancer a phase II study with high-dose cyclophosphamide and high-dose VP 16-213 with autologous bone marrow transplantation was performed. The regimen used was based on a previously reported phase I study. In eight of the nine evaluable patients a response was seen (six PR and two CR). One patient died of treatment related toxicity. Infection is the most important toxicity. The response duration was short. This combination is a suitable "late intensification' regimen for patients with minimal residual disease after standard dose induction chemotherapy.
|Number of pages||4|
|Journal||European journal of cancer & clinical oncology|
|Publication status||Published - Dec-1985|